Figure 10.

Intrahippocampal injection of a CCL2 neutralizing antibody completely abrogates the increase in seizures following LPS. A, Experimental protocol. B, Seizure frequency in anti-CCL2 or control IgG-injected animals (Ctrl), 2–4 h after LPS administration. In control animals, seizure frequency is significantly higher than in anti-CCL2 injected animals (two-way ANOVA followed by Holm–Sidak test, p < 0.01). C, Total time spent in seizures in anti-CCL2 or control IgG-injected (Ctrl) animals, 2–4 h after LPS administration. In control IgG-injected animals (Ctrl), total duration of ictal activity is significantly higher than in anti-CCL2 injected animals (two-way ANOVA followed by Holm–Sidak test, p < 0.001). D, Mean seizure duration in anti-CCL2-injected and control animals before (baseline) and after LPS administration. Mean seizure duration was unaffected by anti-CCL2 + LPS treatment (one way ANOVA, p = 0.3). E, Total time spent in interictal activity (normalized to the baseline period). Anti-CCL2 prevented the LPS-mediated increase of interictal activity (two-way repeated-measures ANOVA followed by Holm–Sidak test, p < 0.01). F, Number of isolated spikes per 10 min of recording (normalized to the baseline period). No difference was found between anti-CCL2 injected and control IgG-injected (Ctrl) epileptic mice, 2–4 h after LPS administration (two-way repeated-measures ANOVA, p = 0.7). **p < 0.01; ***p < 0.001.